[Benign endometrial lesions induced by tamoxifen].
Tamoxifen is a nonsteroidal antiestrogen drug which has some estrogen agonist activity on the female genital tract. This influence could generate endometrial modifications. The most important lesion is adenocarcinoma but it remains very rare and most lesions are benign. Among them, glandulo-cystic atrophy seems to be the most typical effect of this drug upon the uterine cavity. Development of polyps or hyperplasia is also more frequent among Tamoxifen users than same patients not receiving this treatment. Uterine follow-up could be done by means of endovaginal ultrasonography or hysteroscopy.
De Muylder
X
X
Service de Gynécologie, Clinique Saint-Jean, Bruxelles, Belgique.
D018931:Antineoplastic Agents, Hormonal / Q000009:adverse effects*; D001284:Atrophy / Q000139:chemically induced; D002986:Clinical Trials as Topic; D003560:Cysts / Q000139:chemically induced*; D004714:Endometrial Hyperplasia / Q000139:chemically induced*; D004717:Endometrium / Q000187:drug effects* / Q000473:pathology; D005260:Female; D006801:Humans; D011127:Polyps / Q000139:chemically induced*; D013629:Tamoxifen / Q000009:adverse effects*
D018931:Antineoplastic Agents, Hormonal; D013629:Tamoxifen